-
Oct 21, 2024 | 
consultantlive.com | Raj Chovatiya |George Han |Elizabeth Swanson |Peter Lio
-
Oct 21, 2024 | 
hcplive.com | Raj Chovatiya |George Han |Elizabeth Swanson |Peter Lio
OpinionVideoOctober 21, 2024Author(s):, Oral JAK inhibitors provide a convenient alternative to injectable biologics, potentially enhancing patient adherence in maintenance therapy. These inhibitors target specific inflammatory pathways, offering a tailored approach to managing autoimmune conditions. In rescue treatment, oral JAK inhibitors can quickly modulate immune responses, benefiting patients during disease flares.
-
Oct 21, 2024 | 
hcplive.com | Raj Chovatiya |George Han |Elizabeth Swanson |Peter Lio
OpinionVideoOctober 21, 2024Author(s):, Novel oral systemic agents are being developed, targeting specific pathways in atopic dermatitis pathophysiology for improved efficacy and safety. Personalized medicine approaches and biomarkers are expected to enhance treatment outcomes by tailoring therapies to individual patient profiles. Future treatments aim to provide better disease control, reduce side effects, and improve patient quality of life.
-
Oct 21, 2024 | 
consultantlive.com | Raj Chovatiya |George Han |Elizabeth Swanson |Peter Lio
-
Oct 16, 2024 | 
hcplive.com | Raj Chovatiya |George Han |Elizabeth Swanson |Peter Lio
OpinionVideoOctober 16, 2024Author(s): Patients frequently discuss treatment breaks, influenced by individual treatment responses and personal circumstances. Monitoring during treatment breaks involves regular follow-ups to assess disease activity and manage potential flares. Education and counseling emphasize adherence, recognizing flare signs, and understanding rescue treatments.
-
Oct 16, 2024 | 
consultantlive.com | Raj Chovatiya |George Han |Elizabeth Swanson |Peter Lio
Advances in Oral Systemic Treatments for Management of Atopic Dermatitis - Episode 12Published on: , , , Medical experts rate dermatologists’ comfort with switching to JAK inhibitors and describe how frequently to switch patients from biologics to JAK inhibitors, including their treatment strategy for this population. Video content above is prompted by the following:How would you rate dermatologists’ comfort in switching to a JAK inhibitor?
-
Oct 16, 2024 | 
hcplive.com | Raj Chovatiya |George Han |Elizabeth Swanson |Peter Lio
OpinionVideoOctober 16, 2024Author(s): Dermatologists' comfort with JAK inhibitors is influenced by familiarity and patient-specific factors, affecting their willingness to switch treatments. Switching from biologics to JAK inhibitors is determined by treatment response, side effects, and patient preferences. Treatment strategies involve assessing disease severity, treatment history, and weighing risks versus benefits of JAK inhibitors.
-
Oct 7, 2024 | 
hcplive.com | Raj Chovatiya |George Han |Elizabeth Swanson |Peter Lio
OpinionVideoOctober 7, 2024Author(s): Abrocitinib and upadacitinib provide alternative mechanisms for disease control in patients previously treated with dupilumab. JAK inhibitors may be considered when patients experience inadequate response, loss of efficacy, or adverse effects with dupilumab. Individualized treatment decisions should consider disease severity, treatment history, and JAK inhibitor-associated risk factors.
-
Oct 7, 2024 | 
hcplive.com | Raj Chovatiya |George Han |Elizabeth Swanson |Peter Lio
OpinionVideoOctober 7, 2024Author(s): Setting treatment expectations is vital for building trust and aligning patient-physician goals in oncology. Continuous dialogue about treatment targets keeps patients informed and engaged in their care. Treatment decisions are based on clinical evidence, patient response, and individual preferences. Oncologists consider disease progression, side effects, and quality of life when choosing treatment paths.
-
Oct 7, 2024 | 
consultantlive.com | Raj Chovatiya |George Han |Elizabeth Swanson |Peter Lio
Advances in Oral Systemic Treatments for Management of Atopic Dermatitis - Episode 9Published on: , , , Medical experts discuss the importance of setting treatment expectations and maintaining dialogue with patients about targets and explain how to decide on a new treatment when switching. Video content above is prompted by the following:How important is it to set treatment expectations? Do you have an ongoing dialogue with patients about achieving targets?
